Table 2:

Risk of venous thromboembolism and myocardial infarction among participants in the Copenhagen General Population Study and the Copenhagen City Heart Study

Event; blood type or mutation	Participants*	Events	Events per 10 000 person-years	Age- and sex- adjusted HR (95% CI)	p value‡	Fully adjusted HR† (95% CI)	p value‡
Venous thromboembolism
ABO blood type					< 0.001		< 0.001
O	25 906	718	8.4	1.0		1.0
Non-O	40 095	1 561	11.9	1.4 (1.3–1.5)		1.4 (1.3–1.5)
Factor V Leiden (R506Q)					< 0.001		< 0.001
Noncarrier	60 435	1 891	9.5	1.0		1.0
Heterozygous	5 420	359	20.4	2.2 (2.0–2.5)		2.2 (2.0–2.5)
Homozygous	145	28	63.0	7.0 (4.8–10)		7.0 (4.8–10)
Prothrombin G20210A					< 0.001		< 0.001
Noncarrier	64 623	2 211	10.4	1.0		1.0
Heterozygous	1 369	65	14.6	1.5 (1.1–1.9)		1.5 (1.2–1.9)
Homozygous	8	2	77.7	10 (2.6–41)		11 (2.8–44)
Myocardial infarction
ABO blood type					0.2		0.2
O	25 900	1 035	12.4	1.0		1.0
Non-O	40 087	1 673	13.0	1.0 (1.0–1.1)		1.1 (1.0–1.1)
Factor V Leiden (R506Q)					0.8		1.0
Noncarrier	60 423	2 486	12.7	1.0		1.0
Heterozygous	5 419	217	12.4	1.0 (0.9–1.1)		1.0 (0.9–1.2)
Homozygous	145	5	10.9	0.8 (0.4–2.0)		0.9 (0.4–2.1)
Prothrombin G20210A					0.1		0.04
Noncarrier	64 610	2 644	12.7	1.0		1.0
Heterozygous	1 369	64	14.8	1.3 (1.0–1.7)		1.3 (1.0–1.7)
Homozygous	8	0	0.0	–		–

Note: CI = confidence interval, HR = hazard ratio.

^*The numbers of participants varies slightly because of the exclusion of participants with events before 1977.

^†Adjusted for age, sex, current smoking status, body mass index, systolic blood pressure and diabetes mellitus.

^‡p values are for Wald test or test of trend; genotypes were coded 0, 1 or 2 for noncarrier, heterozygous or homozygous, respectively.